| Popis: |
To report outcomes in cholangiocarcinoma patients treated withNinety-five patients (median age 67 years [IQR: 67, 74]; 50 men) were treated in 27 centers between July 2015-August 2020. Baseline demographics included imaging findings, performance status and previous systemic or locoregional treatments. Dosimetry method was tracked. Overall Survival (OS)/Progression Free Survival (PFS) were calculated by the Kaplan-Meier method. Best imaging response was calculated with RECIST 1.1. Grade/=3 toxicities were assessed using CTCAE v5. Cox regression analysis was performed.Sixty percent (52/86) patients had multifocal and 27% had extrahepatic tumor. The median index tumor diameter was 7.0 cm (IQR: 4.9-10). Activity calculation method was reported in 59 (62%) patients with body-surface area (BSA) most used (45/59, 76%). Median OS for the cohort was 14 months (95% CI, 12-22). OS at 3, 6, 12, and 24 months was 94%, 80%, 63% and 34%. Median OS was longer in patients without cirrhosis (19.1 vs 12.2 months, p=0.05). Cirrhosis, previous chemotherapy (OS 19.1 vs 10.6 months for treatment naïve, p=0.07) and imaging response at 6 months (OS 16.4 vs. 9.5 months for no response, p=0.06) underwent regression analysis. Imaging response predicted OS at regression (HR: 0.39, p=0.008). Grade 3-4 bilirubin toxicities were seen in 5/72 (7%) patients. Grade 3 albumin toxicity was seen in 1/72 (1.4%) patients.Objective response at 6 months predicts longer OS with TARE for cholangiocarcinoma. Liver function toxicity incidence is10%. |
